Bruker Co. (NASDAQ:BRKR) CEO Frank H. Laukien sold 400,000 shares of the company’s stock in a transaction on Thursday, May 30th. The stock was sold at an average price of $41.48, for a total transaction of $16,592,000.00. Following the transaction, the chief executive officer now directly owns 37,991,030 shares in the company, valued at $1,575,867,924.40. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Bruker stock opened at $41.77 on Monday. Bruker Co. has a 52 week low of $26.10 and a 52 week high of $44.47. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.27 and a current ratio of 2.12. The stock has a market capitalization of $6.50 billion, a P/E ratio of 29.84, a price-to-earnings-growth ratio of 2.20 and a beta of 1.44.

Bruker (NASDAQ:BRKR) last released its quarterly earnings data on Thursday, May 2nd. The medical research company reported $0.28 EPS for the quarter, topping the consensus estimate of $0.24 by $0.04. Bruker had a net margin of 9.53% and a return on equity of 26.28%. The business had revenue of $461.40 million for the quarter, compared to analyst estimates of $450.46 million. During the same period in the previous year, the firm earned $0.24 EPS. The business’s revenue for the quarter was up 6.9% compared to the same quarter last year. Analysts forecast that Bruker Co. will post 1.61 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 21st. Investors of record on Monday, June 3rd will be given a $0.04 dividend. The ex-dividend date of this dividend is Friday, May 31st. This represents a $0.16 annualized dividend and a dividend yield of 0.38%. Bruker’s dividend payout ratio is presently 11.43%.

Institutional investors have recently added to or reduced their stakes in the stock. Deutsche Bank AG boosted its position in shares of Bruker by 94.0% in the 4th quarter. Deutsche Bank AG now owns 578,945 shares of the medical research company’s stock worth $17,232,000 after buying an additional 280,533 shares in the last quarter. Dimensional Fund Advisors LP boosted its position in shares of Bruker by 4.8% in the 4th quarter. Dimensional Fund Advisors LP now owns 1,013,763 shares of the medical research company’s stock worth $30,178,000 after buying an additional 46,244 shares in the last quarter. State Board of Administration of Florida Retirement System boosted its position in shares of Bruker by 0.4% in the 4th quarter. State Board of Administration of Florida Retirement System now owns 144,802 shares of the medical research company’s stock worth $4,311,000 after buying an additional 510 shares in the last quarter. Rhumbline Advisers boosted its position in shares of Bruker by 3.3% in the 4th quarter. Rhumbline Advisers now owns 102,048 shares of the medical research company’s stock worth $3,038,000 after buying an additional 3,254 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its position in shares of Bruker by 33.4% in the 3rd quarter. JPMorgan Chase & Co. now owns 96,033 shares of the medical research company’s stock worth $3,213,000 after buying an additional 24,048 shares in the last quarter. Institutional investors and hedge funds own 66.74% of the company’s stock.

A number of equities analysts have recently weighed in on BRKR shares. BTIG Research reaffirmed a “buy” rating and set a $44.00 price target (up from $42.00) on shares of Bruker in a research note on Tuesday, February 12th. BidaskClub raised shares of Bruker from a “buy” rating to a “strong-buy” rating in a research note on Friday, March 22nd. Deutsche Bank raised shares of Bruker from a “hold” rating to a “buy” rating and upped their price target for the stock from $40.00 to $50.00 in a research note on Friday, April 12th. Zacks Investment Research cut shares of Bruker from a “buy” rating to a “hold” rating in a research note on Tuesday, April 16th. Finally, Leerink Swann raised shares of Bruker from a “market perform” rating to an “outperform” rating in a research note on Friday, May 3rd. One analyst has rated the stock with a sell rating, three have given a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $43.71.

TRADEMARK VIOLATION WARNING: “Insider Selling: Bruker Co. (BRKR) CEO Sells 400,000 Shares of Stock” was first reported by Watch List News and is owned by of Watch List News. If you are viewing this report on another website, it was copied illegally and republished in violation of United States and international copyright law. The correct version of this report can be viewed at https://www.watchlistnews.com/insider-selling-bruker-co-brkr-ceo-sells-400000-shares-of-stock/3029804.html.

Bruker Company Profile

Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry solutions; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.

Featured Article: What strategies should day traders use to execute a trade?

Receive News & Ratings for Bruker Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker and related companies with MarketBeat.com's FREE daily email newsletter.